<html>
<head>
<meta charset="UTF-8"/>
<meta name="tikaGenerated" content="true"/>
<meta name="date" content="2015-11-19T00:05:54Z"/>
<meta name="xmp:CreatorTool" content="PDFCreator Version 1.7.3"/>
<meta name="Keywords" content="Public - I2 - A1"/>
<meta name="dc:creator" content="rallde01"/>
<meta name="dcterms:created" content="2015-11-19T00:05:54Z"/>
<meta name="Last-Modified" content="2015-11-19T00:05:54Z"/>
<meta name="dcterms:modified" content="2015-11-19T00:05:54Z"/>
<meta name="title" content="TP-L3-419 v1.1 November 2015 Privigen 10% administration guidelines"/>
<meta name="Last-Save-Date" content="2015-11-19T00:05:54Z"/>
<meta name="meta:save-date" content="2015-11-19T00:05:54Z"/>
<meta name="dc:title" content="TP-L3-419 v1.1 November 2015 Privigen 10% administration guidelines"/>
<meta name="modified" content="2015-11-19T00:05:54Z"/>
<meta name="Content-Type" content="application/pdf"/>
<meta name="creator" content="rallde01"/>
<meta name="meta:author" content="rallde01"/>
<meta name="dc:subject" content="Public - I2 - A1"/>
<meta name="meta:creation-date" content="2015-11-19T00:05:54Z"/>
<meta name="created" content="Thu Nov 19 10:35:54 ACDT 2015"/>
<meta name="xmpTPg:NPages" content="2"/>
<meta name="Creation-Date" content="2015-11-19T00:05:54Z"/>
<meta name="meta:keyword" content="Public - I2 - A1"/>
<meta name="Author" content="rallde01"/>
<meta name="producer" content="GPL Ghostscript 9.10"/>
</head>
<body>
<pre>
PRIVIGEN  10% Intravenous Immunoglobulin 

Page 1 of 2 BloodSafe Guide to Administration, Public   I2   A1 TP-L3-419 v1.1 5/11/2015 

 

 

PRIVIGEN  10% is a human intravenous (IV) immunoglobulin (IVIg) solution for IV infusion. 
It is available in Australia as 5 g (50 mL), 10 g (100 mL), 20 g (200 mL) and 40 g (400 mL) vials. 
Always read the Product Information (PI) in the box carefully before commencing. 
WARNING! DO NOT administer PRIVIGEN  10% using infusion protocols for FLEBOGAMMA  10% DIF or 
ANY other brands of IVIg (including FLEBOGAMMA  5% &amp; INTRAGAM  P 6%). 

 

 

STORAGE 
? PRIVIGEN  10% must be stored below 25 C or 

refrigerated in a monitored blood fridge 
(in transfusion service where available). 

? It must not be stored in a domestic/ward refrigerator. 
? Do not freeze. 
? Removal from storage must be documented in the 

register or electronic system for the purposes of 
tracking as per health service procedures 
/transfusion service provider requirements. 

? Do not use after the expiry date. 
? Store protected from light. 
? PRIVIGEN 10% contains no antimicrobial 

preservative. Use in 1 patient, on 1 occasion only. 
? Contact transfusion service provider/product 

provider for advice re handling/return of any unused 
bottles (unopened). 

? Used bottles MUST be discarded in medical waste &amp; 
are not suitable for recycling. 

VISUALLY INSPECT PRODUCT 
? PRIVIGEN  10% should be a clear or slightly 

opalescent, colourless to pale yellow liquid. 
? Do not use solutions that are cloudy or have 

deposits (any sediment or particles) - contact the 
transfusion service provider. 

CONTRAINDICATIONS &amp; PRECAUTIONS 
? Always refer to the full PI. 
? Patients with rare total IgA deficiency should have 

the IVIg product with the lowest IgA content - 
INTRAGAM  P 6% is the preferred product. 

? Contraindicated in those with known hypersensitivity 
to this product. 

? Contraindicated in those with hyperprolinaemia 
(contains proline). 

PRIOR TO ADMINISTRATION 
? Correct reversible risk factors for adverse reactions 

(such as dehydration) before infusion is given. 
? Ensure prescription is complete including the 

BRAND &amp; CONCENTRATION of IVIg prescribed. 
? Check informed consent is documented as per 

health service policy. 

PRIOR TO ADMINISTRATION (continued) 
? Explain procedure to patient, including symptoms of 

possible reactions. 
? Ensure IV access patent. 
? Record baseline observations (TPR &amp; BP) &amp; general 

patient status including pre-existing rashes. 
? Ensure circumstances/situation appropriate to 

proceed. 
? Check resuscitation equipment, including oxygen &amp; 

adrenaline are available &amp; in working order. 
? Read the PI contained in the box. 
? Allow the product to reach room temperature. 

ENSURE RIGHT PATIENT - RIGHT PRODUCT 
? WARNING! Verify correct patient, product (including 

brand &amp; concentration) &amp; prescription. 
? The patient s identity MUST always be confirmed prior 

to administration. 
? Check as per IV medication/health service policy. 

DOCUMENTATION OF BATCH NUMBER 
? All product batch numbers must be documented in the 

patient s medical record   the vials have a peel off 
label with the batch number. 

? The transfusion service provider may also attach peel 
off label(s). 

IV LINE / PUMPS 
? The use of a pump is recommended to ensure 

constant delivery of accurate rates. 
? A new standard IV line or blood administration set 

(170 - 200 micron filter) may be used. 
? Administration from a glass bottle requires a vented 

system. 

MEDICATION / OTHER IV FLUIDS 
? CAUTION! Do not mix or piggy back this product with 

other medications or IV fluids. 
? Administered via a separate IV line. 
? Premedication may be prescribed (e.g. for a history of 

reaction as per treating doctor). 
? Consider clearing the line with 0.9% Sodium Chloride 

solution (Normal Saline) or 5% Glucose on completion 
of infusion. 

 

Disclaimer: This is a guide only and the information contained herein is general in nature and does not correspond to or reflect any 
particular patient's circumstances or condition(s). It is not a substitute for expert opinion and/or clinical advice. Each of the parties 
involved in developing this document expressly disclaims and accepts no responsibility for any undesirable consequences arising from 
relying on the information, products, procedures or services referred to herein. 

 

Produced by SA BloodSafe Program, in conjunction with the SA Immunoglobulin Therapy Advisory Group, based on Australian Product 
information. 



PRIVIGEN  10% Intravenous Immunoglobulin 

Page 2 of 2 BloodSafe Guide to Administration, Public   I2   A1 TP-L3-419 v1.1 5/11/2015 

 

 

 

PRIVIGEN  10% INFUSION RATES 
? Infusion rates should be calculated &amp; prescribed by the 

treating doctor. Use ideal body weight to calculate 
infusion rates in obese patients. 

? Start slowly, increase rate gradually only if tolerated. 
? If the line is not primed with IVIg, consider this volume 

in the timing of rate increases. 
 

PRIVIGEN  10% INFUSION RATES 
NOTE: RATES# below are in mL/kg/hr: 

0.5 mL/kg/hr for 30 minutes 
1.0 mL/kg/hr for 30 minutes 
2.0 mL/kg/hr for 30 minutes 
3.0 mL/kg/hr for 30 mins with max. rate of 400 mL/hr 

Routine use of higher rates is not recommended. 
#Lower max. rate of up to 2 mL/kg/hr (max. 200 mL/hr) 

is recommended in high risk patients e.g. 
&gt; 65 years; diabetics; obese; 
those with pre-existing or risk factors for: 
cardiac disease, renal failure or arterial or venous 
thromboembolism; 
those with hyperviscosity; paraprotein or dehydration 
(for more info see PI &amp; consult treating doctor). 

? In septic patients or those with multiple risk factors, 
discuss timing of IVIg administration with an expert. 

? During an infusion, subsequent vials may commence at 
same rate that preceding vial finished. 

? Each bottle should be completed within 4 hours. 
? It is recommended that subsequent infusions are given 

according to the same protocol (consult treating doctor 
if there has been a change in health status or reaction 
to a previous infusion). 

REACTIONS 
? Tend to be related to the rate of the infusion &amp; are more 

common in certain patient groups - refer to PI. 
? Symptoms/signs may include: dyspnoea, wheezing, 

chest tightness, coughing, changes in blood pressure, 
tachycardia, flushing, fever, rigors, skin rash/urticaria, 
headache, vomiting, nausea &amp; abdominal &amp; back pain. 

 

REACTIONS (continued) 
? If a reaction does occur: 

? stop administration immediately 
? assess vital signs 
? notify the medical officer 
? provide emergency care as required. 

? For minor reactions (headache is most common) the 
infusion can often be restarted cautiously at a slower 
rate after the patient has improved clinically. 

? Follow your institutional procedure for reporting 
adverse events to IVIg. Inform your transfusion 
service/product provider. 

OBSERVATIONS 
Refer to health service policies/procedures for IVIg 
infusions, PI for any specific recommendations, as well as 
considering individual patient factors &amp; consulting with 
treating doctor. 
General recommendations: 
? Close observation is required &amp; patient s general 

status should be monitored regularly throughout the 
infusion. 

? A common approach is to take a TPR &amp; BP: 
? as a baseline prior to commencing 
? each rate increase 
? hourly once maximum rate is achieved 
? on completion 
? if the patient experiences new or increased 

symptoms. 

OBSERVATION POST INFUSION 
The following patients should be monitored for 1 hour after 
completion of the infusion: 
? those who have not had IVIg before 
? those who have switched from another product 
? where there has been a long interval since the last 

infusion 
? where there has been a significant deterioration in 

health 
? those who have had a reaction to the current or 

previous infusion. 
Other patients should be observed for at least 20 minutes. 
Refer to PI, health service procedures &amp; consult treating 
doctor. 

 

Disclaimer: This is a guide only and the information contained herein is general in nature and does not correspond to or reflect any 
particular patient's circumstances or condition(s). It is not a substitute for expert opinion and/or clinical advice. Each of the parties 
involved in developing this document expressly disclaims and accepts no responsibility for any undesirable consequences arising from 
relying on the information, products, procedures or services referred to herein. 

 

Produced by SA BloodSafe Program, in conjunction with the SA Immunoglobulin Therapy Advisory Group, based on Australian Product 
information. 

 

For updates see www.sahealth.sa.gov.au/bloodsafe 
 

 

  


</pre>
</body>
</html>